Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies.
Saved in:
| Title: | Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. |
|---|---|
| Authors: | Ma SC; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China., Tang XR; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Long LL; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Bai X; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Zhou JG; Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany., Duan ZJ; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China., Wang J; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Fu QJ; Department of Community Health, Tufts University, Medford, USA., Zhu HB; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China., Guo XJ; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Zhang YP; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.; Information Management and Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China., Guo ZQ; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Wu DH; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Dong ZY; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China. |
| Source: | Oncoimmunology [Oncoimmunology] 2021 Apr 26; Vol. 10 (1), pp. 1909296. Date of Electronic Publication: 2021 Apr 26. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
